Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC Discovery Receives Research Grant of EUR 600,000

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Munich m4 biotech cluster programme supports research collaboration with the Medical Clinic of the University of Munich on preclinical development of novel compounds for cancer immunotherapy.

4SC AG has announced that its subsidiary 4SC Discovery GmbH, which specializes in the discovery and early-stage research of new compounds, is to receive a research grant of approximately EUR 600,000 for the development of new cancer drugs in the area of personalized medicine.

As part of the Munich-based leading-edge biotech cluster programme m4, the grant will support a research collaboration between 4SC Discovery and the project group for Immune Pharmacology (Dr. Sebastian Kobold) in the department of Clinical Pharmacology headed by Professor Dr. Stefan Endres from the Medical Clinic of the Ludwig-Maximilians University of Munich.

The aim of this collaboration is to advance the preclinical development of so-called TLR7 and TLR8 agonists for use in cancer immunotherapy.

The project is intended to promote the further development of substances which influence the immune system of cancer patients in such a way that the immune system recognizes the cancer cells and destroys them.

Given that the ability of the immune system to react to abnormal cells depends significantly on the immune status and immune competence of the patient, personalized medicine pursues a therapeutic approach which involves a simultaneous biomarker analysis of the particular patients.

The collaboration starts in November 2012 and is scheduled to run for a period of two years.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer of 4SC AG, said: 'Alongside epigenetics and cancer stem cells, cancer immunotherapy is definitely one of the most exciting and dynamic areas of current cancer research. 4SC has been researching this field for years now and we are delighted to receive funding from the Munich biotech cluster of excellence, m4, to further intensify this research. Our objective in this subsidized collaboration with Professor Endres from the Medical Clinic of the University of Munich is to perform preclinical tests on our compounds and optimize them so that we can begin the clinical development of the compounds in patients soon.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
4SC to Present Biomarker Data for Cancer Drug Resminostat at EHA
Data from Phase II SAPHIRE trial in Hodgkin’s lymphoma presented at EHA meeting in Amsterdam.
Monday, June 18, 2012
4SC Announces First Patient Dosed in Phase I/II SHORE Study with Resminostat
The first patient dosed in the study with resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
Friday, January 21, 2011
Scientific News
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Five Genetic Regions Implicated In Cystic Fibrosis Severity
An international consortium of researchers conducted the largest-ever CF genome-wide analysis to find new therapeutic targets.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Genetic Adaptations to Diet and Climate
Researchers found genetic variations in the Inuit of Greenland that reflect adaptations to their specific diet and climate.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Maintaining Healthy DNA Delays Menopause
An international study of nearly 70,000 women has identified more than forty regions of the human genome that are involved in governing at what age a woman goes through menopause.
Stem Cell Research Hints at Evolution of Human Brain
Researchers at UC San Francisco have succeeded in mapping the genetic signature of a unique group of stem cells in the human brain that seem to generate most of the neurons in our massive cerebral cortex.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos